Phase II study of VELCADE [bortezomib] in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142)

Trial Profile

Phase II study of VELCADE [bortezomib] in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Marginal-zone-B-cell-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2009 Actual end date April 2009 added as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top